Mr. Lewis has counseled Fortune 500 and other companies in mergers, acquisitions and cartel cases before the U.S. Federal Trade Commission, the Antitrust Division of the U.S. Department of Justice and various foreign competition agencies. Leveraging his mechanical and aerospace engineering and science background, he has focused on analyzing the competitive dynamics of high technology industries, including telecommunications, computer hardware and software, transportation, pharmaceuticals, power generation and distribution, and financial/payment processing. Mr. Lewis has counseled companies on a wide variety of business practices, with an emphasis on competitor collaborations, third-party dealing, and purchasing, marketing, pricing and sales strategies.
Mr. Lewis’ recent antitrust experience includes representing:
- Spark Therapeutics in its $4.3 billion sale of its burgeoning gene therapies to Roche Group
- Concert Pharmaceuticals in the $250 million sale of its cystic fibrosis drug to Vertex Pharmaceuticals
- SGL Group of Germany in the $400 million sale of its worldwide graphite electrode business to Showa Denko KK of Japan
- Ansys in its $775 million purchase of Livermore Software Technology Company
- Brammer Bio in its $1.7 billion sale to Thermo Fisher Scientific
- Twilio in its $3 billion acquisition of SendGrid
- Onyx Pharmaceuticals in its $10.4 billion acquisition by Amgen
- Parexel in its $5 billion sale to Pamploma Capital
- Xoom Corporation in its $890 million acquisition by eBay
- Teva Pharmaceuticals in its $2 billion sale of its women’s health business
Mr. Lewis is active in the ABA’s Section of Antitrust Law. He was an associate in the Antitrust and Special Commercial Litigation Department at Sidley & Austin from 1994-1996. Prior to attending law school, he worked at E.I. DuPont de Nemours, Inc. as an engineer and capital projects manager.